PharmExec Blog
Follow Us
RSS
Bookstore
Category Archives: Market Access
The Strange Twists and Turns of 'Pay for Delay'
In the arcane world of patent litigation, the term ‘pay for delay’ can be misleading, and as the Washington debate to restrict these deals unfolds, it is becoming apparent that a ban on such settlements may serve to delay generics even further. Is the fresh grass of reform really always greener than the well-seeded status [...]
UN Pact Scuttles Anti-Vaccine Provision
A new international agreement to reduce mercury contamination of air and water was recently adopted by 140 countries, without a proposal that threatened to limit access to vaccines in much of the world. The credit goes to public health authorities and medical experts who challenged a provision blocking production of vaccines with the preservative thimerosal, [...]
Also posted in Emerging Markets, FDA, Global, Legal, Patient Communication, Safety, healthcare Tagged autism, developing countries, patient advocates, patient groups, thimerosol, vaccines, WHO 1 Comment
Pharma Still Doesn't Get Patient Groups
A survey of 600 patient groups worldwide conducted in late 2012 revealed that perceptions of the pharmaceutical industry soured in the past year, mainly due to issues of access, pricing, patient safety and transparency. The Corporate Reputation of Pharma in 2012—the Patient Perspective compared the reputations of 29 leading pharma companies around six different [...]
Also posted in Europe, Safety, Strategy, patient education, pricing Tagged patient groups, patient-centeredness, survey Leave a comment
The African Markets Pharma Can't Ignore
In its new study on pharma market growth in Africa, IMS Health highlights three ‘rising star’ countries from the continent’s sub-Saharan region.
Also posted in Global, healthcare Tagged Africa, Alegeria, Botswana, Egypt, Kenya, Morocco, Nigeria, Pharma, South Africa 3 Comments
Patients on the Picket Line